Are there plans for further studies?
At the time of preparation of this summary, other The results of any future studies will be available
studies were ongoing to further evaluate the RSV on the websites of European Medicines Agency
OA vaccine. and/or the United States National Institutes of
Health.
Where can I find more information about this study?
The detailed title for this research study is:
A phase 2b, open-label, multi-center, extension study to evaluate the safety and immunogenicity of a
revaccination dose of the RSVPreF3 older adults (OA) investigational vaccine administered intramuscularly
18 months post-Dose 2 in adults 60 years and older who participated in the RSV OA=ADJ-002 study.
Clinical studies have unique study numbers. Below are the unique study numbers associated with this
study.
Organization Website Study Number
European Medicines Agency www.clinicaltrialsregister.eu 2020-000692-21
United States National Institutes www.clinicaltrials.gov NCT04657198
of Health (NIH)
Your doctor can help you understand more about this study and the results. You should not make
changes to your care based on the results of this or any single study.
Version 01 of this document was developed and approved by GSK on 09 May 2022. The information in
this summary does not include additional information available after this date.
Use of the data and information contained in this document is unrestricted, provided that it may not be used in applications
by others for regulatory approval of a product. While not required, when using these data, we ask that proper credit or
attribution of GSK as the source of the data be given. GSK disclaims liability for all uses of the data by users of this document,
to the fullest extent permitted by applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are
waived, licensed or otherwise affected.
This document provides a short summary of this study for a general audience. You can find more information in scientific
summaries of the study. Links to those summaries are provided below.